Orchid Pharma enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


5,180	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
7.1	7.1	21.1	3.6	22.6
301	301	174	134	331
5,474	—	—	—	—
294	294	153	131	309
₹914.15	—	—	—	—

1,866	1,866	1,442	1,304	1,020
16.2%	16.2%	12.1%	10.3%	32.5%
0.06×	—	—	—	—

5.10×	—	—	—	—
123.72×	—	—	—	—
1,226.00×	—	—	—	—
1,073	1,233	922	819	666
44.2	33.6	117	111	83.6
4.5	−9.7	82.6	77.4	28.8
—	126	19.2	126	18.6
−264	−264	−131	61.2	−66.3
—	−264	−131	61.2	−66.3
—	390	150	64.8	84.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ORCHPHARMA₹865.00

Orchid Pharma Limited

· Pharma & Health

₹ CrorePeersFDC GUJTHEM IOLCP MOREPENLAB RPGLIFE GUFICBIO INNOVACAP UNICHEMLABMcap ₹5,180 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	5,180.1
- Cash, Equiv & ST Investments	22.6	3.6	21.1	7.1	7.1
+ Total Debt	331.3	134.5	174.2	301.4	301.4
Enterprise Value	—	—	—	—	5,474.4
Net Debt (memo)	308.7	130.9	153.1	294.4	294.4
EV per Share	—	—	—	—	914.15

Total Capital	1,020.0	1,303.9	1,441.5	1,865.7	1,865.7
Total Debt/Total Capital	32.49	10.31	12.09	16.16	16.16
Total Debt/EV	—	—	—	—	0.06

EV/Sales	—	—	—	—	5.10
EV/EBITDA	—	—	—	—	123.72
EV/EBIT	—	—	—	—	1,226.00
Reference Items — Trailing FY Values
Sales	665.9	819.4	921.9	1,232.8	1,073.3
EBITDA	83.6	110.7	117.2	33.6	44.2
EBIT	28.8	77.4	82.6	-9.7	4.5
Operating Cash Flow	18.6	126.0	19.2	125.6	—
Free Cash Flow	-66.3	61.2	-130.9	-264.0	-264.0
FCFF (free cash flow to the firm)	-66.3	61.2	-130.9	-264.0	—
Capital Expenditure	84.9	64.8	150.1	389.6	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.